A case study recently published in Nature Medicine describes a rare mechanism of fatal relapse following chimeric antigen receptor T cell (CAR-T) therapy.
Researchers at the University of Pennsylvania (Penn)—where CAR-T therapies against cancer were first developed—reported that a 20-year-old male patient with B–cell acute lymphoblastic leukemia began to relapse 9 months after receiving the treatment as part of a phase 1 trial of the then-investigational agent CTL019 (tisagenlecleucel, now marketed by Novartis as Kymriah).
Abbasi J. Relapses After CAR-T Therapy. JAMA. 2018;320(18):1850. doi:10.1001/jama.2018.17585
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: